205 results
Page 3 of 11
8-K
EX-99.1
m716b5y
30 Nov 21
Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH
8:10am
8-K
EX-99.1
aa2rg 3s0c1
16 Nov 21
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study
8:53am
8-K
EX-99.1
sqrxwyfpfv onk
10 Nov 21
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021
9:41am
8-K
EX-99.2
wvpqvp
10 Nov 21
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021
9:41am
8-K
EX-99.1
bai4z3k8jxyyxeain
7 Oct 21
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference
4:24pm
8-K
EX-99.1
066w76otp3ksw5ry4
29 Sep 21
Other Events
9:22am
8-K
EX-99.1
c4rcvelc4o7 be46r
13 Sep 21
Regulation FD Disclosure
8:28am
8-K
EX-99.1
2cahemxf16v8tfxtbuc
26 Jul 21
Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders
12:00am
8-K
EX-99.1
g1zntl49l9mlfqida
13 Jul 21
Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a ‘AMBITION’ NASH Trial; All Primary Endpoints Achieved
10:38am
DEFA14A
EX-99.1
1ufuce0s4 w93
25 Jun 21
Additional proxy soliciting materials
4:48pm
8-K
EX-99.1
91wk 7uf9y
25 Jun 21
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting
4:46pm
8-K
EX-99.1
qb1dgk 0vk
9 Jun 21
Hepion Pharmaceuticals to be Added to the Russell Microcap® Index
9:06am
8-K
EX-99.1
pyz10
6 May 21
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH
10:14am
8-K
EX-99.1
nqmb1e273c3 ur
29 Apr 21
Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress
10:07am